Hornsby, Australia
Hornsby, Australia
SEARCH FILTERS
Time filter
Source Type

The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a disease or disorder, such as a proliferative disease (preferably cancer), using compounds of the invention.


News Article | May 25, 2017
Site: marketersmedia.com

— RnRMarketResearch.com adds “Peritoneal Cancer - Pipeline Review, H1 2017” to its store providing an overview of the Peritoneal Cancer therapeutic pipeline with comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. Complete report on H1 2017 pipeline review of Peritoneal Cancer spread across 759 pages is available at http://www.rnrmarketresearch.com/peritoneal-cancer-pipeline-review-h1-2017-market-report.html . Peritoneal Cancer Pipeline report also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. 3-V Biosciences Inc, AbbVie Inc, Adaptimmune Therapeutics Plc, Aduro BioTech Inc, Advenchen Laboratories LLC, Altor BioScience Corp, Amgen Inc, Arrien Pharmaceuticals LLC, Astellas Pharma Inc, Astex Pharmaceuticals Inc, AstraZeneca Plc, Atara Biotherapeutics Inc, AVEO Pharmaceuticals Inc, Bayer AG, BeiGene Ltd, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corp, Celldex Therapeutics Inc, Celsion Corp, CerRx Inc, Clovis Oncology Inc, Critical Outcome Technologies Inc, Dr. Reddy's Laboratories Ltd, Eisai Co Ltd, Eli Lilly and Company, EpiThany Inc, Esperance Pharmaceuticals Inc, Exelixis Inc, F. Hoffmann-La Roche Ltd, Galena Biopharma Inc, Gene Techno Science Co Ltd, Genelux Corp, Genentech Inc, Genor BioPharma Co Ltd, Glycotope GmbH, Gradalis Inc, Hemispherx Biopharma Inc, ImmunoGen Inc, Immunovaccine Inc, Incyte Corp, Innate Pharma SA, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, Lidds AB, Mabion SA, MabVax Therapeutics Holdings Inc, Mateon Therapeutics Inc, MedImmune LLC, Medivir AB, Merck & Co Inc, Merck KGaA, Millennium Pharmaceuticals Inc, MolMed SpA, Mycenax Biotech Inc, NewLink Genetics Corp, Novartis AG, Novogen Ltd, Oasmia Pharmaceutical AB, OBI Pharma Inc, Oncobiologics Inc, Oncolix Inc, Oncolytics Biotech Inc, OncoMed Pharmaceuticals Inc, Ono Pharmaceutical Co Ltd, Oxford BioMedica Plc, Pfizer Inc, Pharma Mar SA, Polaris Pharmaceuticals Inc, PsiOxus Therapeutics Ltd, Richter Gedeon Nyrt, Samyang Holdings Corp, Sanofi, Sanofi Pasteur SA, Sotio AS, Syndax Pharmaceuticals Inc, TapImmune Inc, Tyrogenex Inc, Vascular Biogenics Ltd, VentiRx Pharmaceuticals Inc, Verastem Inc Get Discount on This Report At http://www.rnrmarketresearch.com/contacts/discount?rname=1001938 (This report is available at upto 25% Discount till 02 June 2017.) Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy. Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 12, 60, 36, 11, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 4 and 1 molecule, respectively. Direct Purchase of This Research Report at http://www.rnrmarketresearch.com/contacts/purchase?rname=1001938 . Scope of this report: The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer and reviews pipeline therapeutics for Peritoneal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Peritoneal Cancer therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Peritoneal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Peritoneal Cancer. About Us: RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.rnrmarketresearch.com/peritoneal-cancer-pipeline-review-h1-2017-market-report.html


The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a proliferative disease, preferably cancer, using compounds of the invention.


The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a disease or disorder, such as a proliferative disease (preferably cancer), using compounds of the invention.


The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a proliferative disease, preferably cancer, using compounds of the invention.


Patent
Novogen | Date: 2011-06-23

There is described a method for the treatment or prevention of menopausal symptoms or osteoporosis wherein there is administered to a subject in need of such treatment a therapeutically effective amount of the isotlavone formononetin, or a method for the treatment or prevention of menopausal symptoms wherein there is administered to a subject in need of such treatment a therapeutically effective amount of the isoflavone daidzein, the isotlavone being optionally administered with one or more pharmaceutically acceptable adjuvants, carriers and/or excipients. Therapeutic uses and compositions/foods are also described, comprising daidzein or formononetin optionally in association with one or more pharmaceutically acceptable adjuvants, carriers, food components and/or excipients.


Patent
Novogen | Date: 2011-06-17

This invention relates to natural products containing phyto-oestrogens, or phyto-oestrogen analogues, which have various beneficial physiological effects in man, and which have a variety of uses, such as to promote good health and as a dietary additive, for example. The invention describes a method of improving the health of a human by administering to the human a health supplementing amount of a phyto-oestrogen selected from genistein, daidzein formononentin and/or biochanin A. A health supplement comprising a health supplementary amount of a phyto-oestrogen selected from genisten daidzein formononentin and/or biochanin A, is also described. Preferably, the supplement also comprises at least one dietary suitable excipient, diluent, carrier or food, and may be in the form of a tablet or capsule, for example. Ideally, the phyto-oestrogen is extracted from red clover or from soya, although any source rich in isoflavones may also be used. The supplement can be used to prevent or ameliorate such conditions as breast cancer, benign breast disease, pre-menstrual syndrome, or symptoms associated with menopause in women, or various types of cancer, and especially for high blood cholesterol levels in all humans, for instance.


Therapeutic method of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (I), in which Z is H, R_(1 )is H or R_(A)CO wherein Ra is C_(1-10)alkyl or an amino acid, R_(2 )is H, OH or OR_(B )where R_(B )is an amino acid, or COR_(A )where R_(A )is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c) or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (f) and B is (g) where R_(3 )is H, COR_(A )where R_(A )is as previously defined, CO_(2)R_(C )where R_(C )is C_(1-10)alkyl, or COR_(B )where R_(B )is as previously defined, R_(4 )is H, COR_(D )where R_(D )is H, OH, C_(1-10)alkyl or an amino acid, CO_(2)R_(C )where R_(C )is as previously defined, COR_(E )where R_(E )is H, C_(1-10)alkyl or an amino acid, COOH, COR_(C )where R_(C )is as previously defined, or CONHR_(E )where R_(E )is as previously defined, R_(5 )is H, CO_(2)R_(C )where R_(C )is as previously defined, or COR_(C)OR_(E )where R_(C )and R_(E )are as previously defined, and where the two R_(5 )groups are attached to the same group they are the same or different, R_(6 )is H or hydroxyl C_(1-10)alkyl, X is preferably O, but may be N or S, and Y is (h) where R_(7 )is H, or C_(1-10)alkyl.


Compositions enriched with natural phyto-oestrogens or analogues thereof selected from Genistein, Daidzein, Formononetin and Biochanin A. These may be used as food additives, tablets or capsules for promoting health in cases of cancer, pre-menstrual syndrome, menopause or hypercholesterolaemia.


Patent
Novogen | Date: 2015-02-05

The present invention relates broadly to anti-cancer agents. In particular, the present invention relates to selected benzopyran compounds, the preparation thereof, and their use in methods for treating cancer and reducing the incidence or risk of cancer recurrence.

Loading Novogen collaborators
Loading Novogen collaborators